SR1

StemRegenin 1 (SR1) is an aryl hydrocarbon receptor (AhR) inhibitor.

SR10067 is a potent, selective, and brain-penetrant agonist of Rev-Erbβ (IC50 = 160 nM) and Rev-Erbα (IC50 = 170 nM) with anxiolytic activity.

SR1664 is a potent and selective PPARγ inhibitor with potential antidiabetic activity. SR1664 binds to PPARγ and potently inhibits Cdk5-mediated PPARγ phosphorylation (IC50 = 80 nM; Ki = 28.67 nM) without exhibiting PPARγ agonist activity.

SSR126768A is a novel and selective, orally active and potent oxytocin (OT) receptor antagonist with inhibitory effects on uterine contractions for the prevention of preterm labor.

SSR180711 hydrochloride (SSR-180711A HCl) is a selective Alpha7 nicotinic acetylcholine partial agonist for the study of neurodegenerative and cognitive disorders.

SR17018, a mu-opioid receptor (MOR) agonist, binds with GTPγS and has an EC50 of 97 nM.

SR1078 is an agonist of retinoic acid receptor-related orphan receptor (ROR)α γ.

SR12813 (GW 485801) is a pregnane X receptor (PXR) agonist.

SR15006 is Krüppel-like factor 5 (KLF5) inhibitor (IC50 = 41.6 nM).

SR121566A is a novel non-peptide antagonist of Glycoprotein IIb IIIa (GP IIb-IIIa).

SSR128129E (free acid) is an orally available, allosteric inhibitor of FGFR, with an IC50 of 1.9 μM for FGFR1.

SR144528 is an antagonist of the CB2 receptor (Ki = 0.6 nM) and inhibits microsomal ACAT activity (IC50 = 3.6 μM).

SR18662, an optimized compund based on ML264 that inhibits Krüppel-like factor 5 (KLF5) with IC50 of 4.4 nM, reduces the viability of multiple colorectal cancer cell lines and induces apoptosis.

SR11237 is a Pan retinoid X receptor (RXR) agonist. SR11237 causes RXR RXR homodimers to form and transactivate a reporter gene containing a RXR-response element.

SR14150 is a partial agonist of high-affinity NOP receptor.

SR1555 is a selective RORγ inverse agonist that inhibits the development and function of TH17 cells, a subset of T cells that have been involved in the pathology of several autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.

SR142948A is a selective and reversible non-peptide neurotensin receptor antagonist capable of blocking hypothermia and analgesic effects induced by intracerebroventricular injection of NT, and capable of concentration- and volume-dependent blockade of NMDA-induced dopamine release.

SR 1001 is an inverse agonist for RORα RORγ (Kis: 172 111 nM).

SSR128129E (SSR) is an allosteric and orally-active FGFR1 inhibitor (IC50: 1.9 μM), but not affecting other related RTKs.

HSR1304 (Compound 5d) is a potent inhibitor of NFκB, a multifunctional transcription factor implicated in various human diseases, including cancer and chronic inflammation. It shows significant potential for cancer research.

SR12418 is a specific REV-ERB synthetic ligand that acts on REV-ERBα (IC50: 68 nM) and REV-ERBβ (IC50: 119 nM) and can be used to study experimental autoimmune encephalomyelitis (EAE) and colitis.

SR-1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR). It is an inverse agonist of RORγ and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPAR) but does not activate it. SR-1903 inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1). It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1. SR-1903 reduces the severity of collagen-induced arthritis. It reduces blood glucose levels in a glucose tolerance test, serum levels of total cholesterol and LDL, body weight, and fat mass in a mouse model of high-fat diet-induced obesity.

SR1555 hydrochloride is the hydrochloride salt form of SR1555. It acts as an inverse agonist for the retinoic acid receptor-related orphan receptor γ (RORγ), with an IC50 of 1 μM. This compound inhibits the development and function of pro-inflammatory TH17 cells while increasing the frequency of anti-inflammatory regulatory T (Treg) cells. SR1555 hydrochloride is utilized in research related to autoimmune diseases.